Impact of Monosodium Glutamate on 68GA-PSMA-11, PET Imaging Biodistribution in Patients With Prostate Cancer (MSG PSMA PET)
Prostate Carcinoma
About this trial
This is an interventional diagnostic trial for Prostate Carcinoma
Eligibility Criteria
Inclusion Criteria:
- Patient volunteer to undergo 2 PSMA PET/CT scans within 14 days
- Histopathologically proven prostate cancer (PCa)
PSMA PET/CT indicated for :
- Initial staging before definitive therapy
- Biochemical recurrence localization
- Metastatic disease re-staging
- Ability to understand a written informed consent document and the willingness to sign it
- Ability to ingest 300 mL of fluid across 10 minute period
Exclusion Criteria:
- Prior salivary gland surgery or radiation therapy
- Prior history or current salivary gland disease
- Unable to lie flat, still or tolerate a PET scan
- Unable to follow the salivary flow stimuli administration regimen
- Unable to follow the glutamate supplementation administration regimens
- Asthma
- Severe uncontrolled hypertension (systolic blood pressure above 140 mm Hg and diastolic blood pressure above 90 mm Hg, or systolic blood pressure above 180 mm Hg, or diastolic blood pressure above 110 mg Hg). Patients with controlled hypertension under medication are eligible
- Sodium/salt restricted diet due to other medical conditions
- History of severe asthma that has led to hospitalizations or emergency room visits
- History of severe contraindications to MSG consumption including severe headaches, migraines or other intolerance
- Change to treatment administered between time of baseline scan and MSG scan
Sites / Locations
- UCLA / Jonsson Comprehensive Cancer Center
Arms of the Study
Arm 1
Arm 2
Experimental
Experimental
Arm I (68GA-PSMA-11, PET/CT, monosodium glutamate)
Arm II (68GA-PSMA-11, PET/CT, monosodium glutamate)
8 patients receive gallium Ga 68-labeled PSMA-11 IV and PET/CT scan on day 1. Within 2 weeks (days 2-14), patients receive MSG PO over 10 minutes and receive a second dose of gallium Ga 68-labeled PSMA-11 IV, followed by a second PET/CT scan. Patients also undergo collection of saliva at 0, 30, and 60 minutes after gallium Ga 68-labeled PSMA-11 injection and 90 minutes after PET/CT.
8 patients receive gallium Ga 68-labeled PSMA-11 IV and undergo a PET/CT scan on day 1. Within 2 weeks (days 2-14), patients receive a second dose of gallium Ga 68-labeled PSMA-11 IV immediately followed by MSG applied in the mouth over 30 seconds every 10 minutes for a total of 6 times, and then undergo a second PET/CT scan. Patients also undergo collection of saliva at 0, 30, and 60 minutes after gallium Ga 68-labeled PSMA-11 injection and 90 minutes after PET/CT.